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MinireviewThe HIV-1 Vaccine Race
the average number of people who become infected byDavid D. Ho1 and Yaoxing Huang
an index case. Similarly, the speed of HIV-1 spreadAaron Diamond AIDS Research Center
within a newly infected person could be assessed byThe Rockefeller University
determining a reproductive ratio, R0, that refers to the455 First Avenue
mean number of cells that become infected de novo byNew York, New York 10016
a single infected cell. As shown in Figure 1 (Nowak et
al., 1997; Little et al., 1999; Stafford et al., 2000), this
number is shaped by several factors, including the effi-There is an urgent need to come up with a vaccine
ciency with which HIV-1 infects a CD4 T cell (infectivitythat will curtail the spread of HIV-1. To be successful,
constant), the number of virions produced by one in-the scientific community must work in concert to de-
fected cell (burst size), the rate of virion clearance byvelop sound strategies based on a deeper understand-
the body, and the death rate of productively infecteding of the virus. Significant technological advances
CD4 T cells. Using serial plasma viral load data fromare also required to overcome the unique obstacles
patients during acute infection, together with quantita-posed by HIV-1. Some of the challenges we face in
tive analyses based on the most recent understandingthis endeavor are discussed here.
of HIV-1 replication dynamics, Little et al. (1999) and
Stafford et al. (2000) have indirectly calculated R0 to be
in the range of 3 to 34 per viral generation. Similarly,The HIV-1 epidemic rages on, despite increased under-
Nowak et al. (1997) have estimated R0 to be 5 to 68 forstanding of the causative agent and recent advances
SIV isolate E660. However, it should be emphasized thatmade in antiretroviral therapy. Cumulatively, the virus
these values are only crude estimates, because they arehas infected over 60 million individuals, having killed
inferred from inadequate data. We sorely need a preciseapproximately 22 million while leaving about 40 million
measurement of R0 that is derived by directly measuringliving with an infection that is ultimately fatal if left un-
the rate of expansion of infected cells in lymphoid tis-treated. Each day, HIV-1 infects another 14,000 persons
sues. An accurate determination would tell us not onlyworldwide, most of whom live in developing countries.
the true speed of HIV-1 growth during a most criticalNo doubt, the biomedical research community is locked
period of infection, but also the magnitude of our taskin a desperate race to come up with a vaccine that could
in achieving vaccine protection. Our goal in HIV-1 vacci-slow or stop the further spread of HIV-1.
nation is to induce preexisting virus-specific immunityWhat is expected of an HIV-1 vaccine? As with any
that would rapidly expand to reduce R0 of the invadervaccine, it should train the immune system to recognize
to a value1, when infected cell population is expectedthe invading microbial pathogen. Moreover, it should
to contract with each successive generation.induce and sustain a level of immunological memory
Given the practical limitations, how do we accuratelysufficient to allow rapid expansion of immune effectors
measure R0 during acute HIV-1 infection? We believe athat would shut down or slow the growth of the microor-
feasible approach is to study monkeys during acuteganism immediately after initial infection. In other words,
infection by SIV strains with kinetics resembling HIV-1,the vaccine should give the immune system a head start
and to directly and serially quantify the number of pro-in a race to eliminate or control the invader so that it
ductively infected cells in lymph nodes during the expo-cannot gain a foothold in the new host.
nential viral growth phase of primary infection. Concur-The Race: HIV-1 versus Virus-Specific Immunity
rently, sequential data on plasma viremia must be
In any race, it would seem prudent to know how fast
collected so that such results could be correlated to
the opponent could run. This information, in turn, would
direct measurements of R0. Armed with such a correla-tell us how hard we must train and what speed we must tion, we should be able to reliably calculate R0 for theachieve. Also, in a race against a deadly killer, there is spread of HIV-1 during primary infection in humans
no shame in devising tricks to trip up or slow down our based on only sequential plasma viral load data.
foe. Yet, surprisingly little is known about the speed of How can we slow down HIV-1? Looking at the determi-
HIV-1 growth in vivo during the initial period of infection. nants of R0, it is likely that the parameters  and d will
This gap in our knowledge is attributable to logistical not be affected by vaccination. On the other hand, the
difficulties in finding newly infected individuals at a time term k/c could be lowered by vaccine-elicited antibodies
when the virus is undergoing exponential growth imme- that either neutralize or opsonize HIV-1, whereas the
diately prior to the onset of symptoms of primary HIV-1 term / could be reduced by cytotoxic T lymphocytes
infection. Nevertheless, two observational studies (Little (CTL) that either suppress viral replication or facilitate
et al., 1999; Stafford et al., 2000) and one experimental the death of infected cells. It is also obvious that combi-
study (Nowak et al., 1997) have provided hints on the nation of humoral and cellular immune responses would
kinetics of these viruses during the time frame most have multiplicative, not just additive, effects on R0.
relevant to vaccine protection. A closer examination of the equation in Figure 1 is
The rate of spread of an epidemic infection in a popu- quite informative as to what HIV-1 vaccination must
lation is judged by measuring the reproductive ratio, i.e., achieve in order to be protective. Hypothetically, if a
vaccine elicits a virus-neutralizing activity of 80% in neat
serum and no cellular immune responses whatsoever,1Correspondence: dho@adarc.org
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Figure 1. The HIV-1 Reproductive Ratio, R0, and Its Determinants
Figure 2. HIV-1 Envelope Glycoproteins, gp120 and gp41
The coding sequence of gp120 is shown at the top of the left panel,then k and R0 would each be reduced to 20% of expected
with the 5 variable domains shaded in color. The core structure ofvalues. Protection against HIV-1 infection would be at-
gp120 is derived from Wyatt and Sodroski (1998). The stems of
tained only in newly infected cases whose R0 would the variable loops are as indicated, along with regions with heavy
have been 5 in the absence of vaccination. Next, let glycosylation. The contact residues for CD4 are shaded in brown,
us examine the impact of a different vaccine that induces whereas those for CCR5 are shown in green. The binding sites for
monoclonal antibodies b12 and 2G12 are as denoted. The coding50% serum antibody neutralizing activity as well as a
sequence of gp41 is shown at the top of the right panel, with heptadCTL response that decreases the viral burst size by 60%
repeat-1 (HR-1), heptad repeat-2 (HR-2), and transmembrane (TM)and increases the death rate of productively infected
regions shaded in color. ELDKWAS is a stretch of amino acids
cells by 30%. Although these changes are modest indi- known to form at a part of the epitope for monoclonal antibody 2F5,
vidually, together they lower R0 by almost 85%. Thus, and its approximate location is indicated by *. The figures for the
if this hypothetical vaccine had been administered to 6-bundle, coiled coil structure is derived from Chan and Kim (1998).
individuals studied by Stafford et al. (2000) prior to their
HIV-1 infection, protection would have been observed
in 6 of 10 cases. These examples not only point to ciable antibodies capable of neutralizing primary strains
of HIV-1.multiprong strategies to slow HIV-1, but also serve to
emphasize the importance of measuring R0 in newly On the other hand, it is certain that antibodies can
have a profoundly positive effect on slowing the replica-infected persons.
The dynamics of virus replication during initial infec- tion of HIV-1 (Poignard et al., 2001). The rapid emer-
gence of neutralization-resistant viral variants is indica-tion should also be kept in mind when interpreting re-
sults from vaccine protection experiments in monkeys. tive of a strong selective pressure exerted by antibodies
in vivo. In addition, passive infusion of neutralizing anti-In most cases, studies have been done using SIV or SIV-
HIV recombinants (SHIV) that are “faster” (higher R0’s) bodies can protect monkeys from SHIV infection. Fur-
thermore, several monoclonal antibodies have beenthan typical HIV-1. Moreover, the challenge virus is often
given a significant head start because of the large viral shown to have reasonably potent and broad neutralizing
activity against primary strains of HIV-1. For example,inoculum used. It is therefore expected that results of
vaccine protection experiments in such monkey models monoclonal antibody b12 binds a region of gp120 that
overlaps with the CD4 contact site, whereas 2G12 rec-might appear overly pessimistic.
Lowering k/c: Antibodies against HIV-1 ognizes a domain near the receptor and coreceptor
binding sites (Figure 2). Another antibody, 2F5, is di-Primary strains of HIV-1 are particularly refractory to
antibody neutralization (Poignard et al., 2001), a phe- rected against a sequence within the transmembrane
glycoprotein, gp41. While these antibodies have the de-nomenon first seen when soluble CD4 was administered
to patients. This antibody resistance is primarily a reflec- sired properties, we have yet to figure out a way to elicit
such antibodies using envelope-based immunogens.tion of the intrinsic properties of the external envelope
glycoprotein, gp120 (Figure 2). N-linked glycosylations A particularly important area of vaccine research is
to take advantage of the gp120 structural informationon over 20 sites typically account for half of the molecu-
lar mass of gp120, the surface of which is further covered to guide the design of novel envelope immunogens.
Specifically, elements that shield the functional domainsby five highly variable sequences. These elements shield
the functional, conserved domains from antibody recog- of the molecule could be surgically removed. Preliminary
studies have found that deletion of variable loops ornition, including receptor (CD4) and coreceptor (CCR5)
binding sites (Wyatt and Sodroski, 1998). Perhaps for elimination of glycosylation sites can yield modified
gp120’s that induce stronger neutralizing antibody titersthis reason, vaccine approaches that are largely based
on the induction of neutralizing antibodies, such as killed in animals (Poignard et al., 2001). Another recent ap-
proach is to construct trimeric gp120 to mimic the nativewhole virus and recombinant envelope vaccines, have
not been deemed promising (McMichael and Hanke, spike on the virion surface. While such constructions
have been successful, there are still no reports that the2002; Poignard et al., 2001). Nevertheless, a monomeric
gp120 vaccine has entered phase III clinical trials de- trimeric gp120 molecules could better raise neutralizing
antibodies. As the vaccine effort moves forward, it isspite its inability to elicit, in animals or humans, appre-
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imperative that a concerted effort be devoted to modi-
fying gp120 so that its functional domains could be
rendered more immunogenic.
Similarly, a serious effort should be made to manipu-
late gp41 to expose its critical elements to the humoral
immune system. Considerable structural information is
available on how the heptad repeats in the gp41 trimer
interact in an antiparallel manner to form a 6-bundle,
coiled coil structure (Figure 2) that is a prerequisite for
approximating the viral and cellular membranes for fu-
sion (Chan and Kim, 1998). Two sets of observations
suggest that antibodies might be able to block this es-
sential step. First, peptide homologs of heptad repeat-2
are known to inhibit HIV-1 entry into a cell, presumably
by competitively interfering with the 6-bundle formation.
Second, the epitope of 2F5 maps to a stretch of amino
acids, ELDKWAS, immediately distal to heptad repeat-2
(Figure 2). Synthetic peptides containing this sequence, Figure 3. Timeline of Key Events in the Life of an HIV-1-Infected T
however, have failed to elicit neutralizing antibodies. Cell, and Hypothetical Profiles for Progeny Virion Production
Nevertheless, it is clear that reconfiguring gp41, in whole
or in part, is likely a fruitful strategy to induce the desired stories provide much of the current optimism in HIV-1
humoral response against HIV-1. vaccine development.
Lowering /: Cellular Immunity against HIV-1 It is of course important that vaccine-mediated bene-
In recent years, HIV-1 vaccine strategies have shifted fits be sustained over time. In this regard, it is disappoint-
toward the induction of virus-specific cell-mediated im- ing to learn that two vaccinated, initially protected mon-
munity, in part because of the difficulty in eliciting neu- keys eventually broke through with uncontrolled viremia
tralizing antibodies. But another major reason is the as a result of viral escape from CTL responses (Barouch
growing awareness of the importance of CTL in control- et al., 2002). This observation should not come as a
ling HIV-1/SIV replication in vivo (McMichael and Hanke, surprise, given the propensity for the virus to mutate,
2002). The initial control of viremia following primary and knowing that these monkeys were immunized
infection is temporally correlated with the onset of spe- against only two viral antigens. Perhaps herein lies a
cific CTL responses. SIV replication in macaques in- reminder of a lesson we have already learned from anti-
creases dramatically when a monoclonal antibody is used retroviral therapy. The best way to maintain durable con-
trol is to apply strong pressure on several spots simulta-to deplete CD8 T cells. Moreover, the strong pressure
neously. It then follows that broader immune responsesexerted by cellular immunity in vivo is apparent from the
directed against multiple viral proteins would be supe-rapid emergence of CTL-escape viruses.
rior in the long run. It is unfortunate that too many ofA specific CTL response is difficult to induce by im-
the HIV-1 vaccines under development today incorpo-munizing with killed whole virus particles, recombinant
rate only one or two viral antigens.proteins, or synthetic peptides because the proper anti-
The success of the prime-boost strategy in monkeygen-presentation pathway requires endogenous protein
experiments has propelled a number of candidate vac-expression. It is thus not surprising that live attenuated
cines into clinical trials. A DNA vaccine and a recombi-virus vaccines can raise virus-specific CTL. While live
nant vaccinia, each containing gag as well as a stringattenuated SIV vaccines have shown a great deal of
of CTL epitopes from subtype A of HIV-1, are well intosuccess in monkey experiments, their use as a vaccine
phase I testing in England and Kenya (McMichael andstrategy to protect humans from HIV-1 is generally con-
Hanke, 2002). Likewise, a DNA vaccine and a recombi-sidered infeasible and unsafe. In light of this, recent
nant adenovirus-5, each carrying a subtype-B gag, haveattention has turned to the use of DNA vaccines and
entered human trials in the U.S. (Shiver et al., 2002).live viral vectors, including vaccinia, canarypox virus,
While these efforts are generally regarded as promising,adenovirus, adeno-associated virus, alphavirus, and ve-
there is also no doubt that in the years to come technical
sicular stomatitis virus. Since these approaches have
refinement of vaccine candidates will be necessary (1)
no precedent among currently licensed vaccines, their to enhance the level and persistence of antigen expres-
eventual development will undoubtedly face new scien- sion, (2) to enlarge the capacity to include more viral
tific obstacles as well as manufacturing, regulatory, and genes, (3) to increase vaccine stability, (4) to improve
ethical challenges. These issues notwithstanding, a sig- the efficiency of vaccine production, and (5) to avoid
nificant number of studies have been performed in ma- preexisting immunity directed to the viral vector.
caques against SIV or SHIV infection (McMichael and A better understanding of the kinetics of HIV-1 infec-
Hanke, 2002), either using DNA immunization alone or tion of a CD4 T cell will contribute substantially to our
priming with a DNA vaccine followed by boosting with a vaccine strategy as well. Vaccine-induced CTL responses
recombinant vaccinia (Amara et al., 2001) or adenovirus should decrease  and increase , thereby lowering R0
(Shiver et al., 2002) carrying one or several viral genes. (Figure 1). Yet the magnitude of these changes depends
In each of these cases, vaccination led to protection very much on the timing of key events in the lifespan of
against high levels of viremia and disease progression, an infected cell in relationship to its recognition and
killing by CTL. As shown in Figure 3, rough estimatesbut not against infection per se. These partial success
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are available on the timing of viral entry, reverse tran- Choosing the incorrect virus for vaccine development
scription, integration, and transcription. Viral dynamics also runs a political risk of equal significance. One exam-
studies have also revealed the eclipse phase of the viral ple is sufficient to illustrate the point. Many candidate
life cycle (when no progeny virus is made) to be about vaccines are made using subtype-B viruses because
one day, and the lifespan of a productively infected T vaccine producers are typically based in the U.S. or
cell to be an additional day. Relatively little is known, Europe. Should such a vaccine prove to be safe and
however, about the precise timing of expression of early immunogenic, it will eventually have to be tested for
versus late gene products by an infected cell. Two de- efficacy in an area with high incidence of HIV-1 infection,
cades into the AIDS epidemic, we still have no idea which in all likelihood will be a developing country where
which of the three kinetic profiles for virus production other viral subtypes are prevalent. However, resistance
in Figure 3 is closest to the truth. Importantly, we also from the host nation to the clinical trial is likely to be
do not know the kinetics of recognition and destruction strong because of the specter of exploitation, i.e., the
of an infected cell by CTL. Yet each of the missing pieces perception, whether true or not, that the developing
of information could have profound influences on  and country is being used as the testing ground for a vaccine
, and consequently on R0. For example, if CTL act very that is ultimately intended for wealthier countries. Such
late in the viral life cycle, then a slight shortening of the political and ethical predicaments, together with scien-
lifespan would result in a large reduction in the burst tific considerations discussed previously, underscore
size for the red profile in Figure 3, but much less so for the need to think through the vaccine development and
the green profile. We must quickly acquire the missing testing strategy in its entirety before embarking on vac-
kinetic information, because it could refine our strategy cine design.
to outrace HIV-1. Conclusion
A Hurdle in the Race: HIV-1 Diversity President Clinton declared in 1997 that an HIV-1 vaccine
The diversity of HIV-1 is great, but its impact on vaccine would be developed in a decade’s time. Given the pro-
development remains uncertain. Due to its dynamic na- tracted timeline required for clinical trials in this field,
ture of replication and high error rate during reverse one of the current vaccine candidates must succeed in
transcription, HIV-1 has evolved into multiple subtypes order for us to cross that finish line on time. There is a
or clades, which are partly shaped by selective forces in chance, but it is not great. Time notwithstanding, ulti-
the host, including the immune response. Intra-subtype mate success will result from a combination of deeper
diversity could be as large as 20%, and inter-subtype fundamental knowledge and sound technological inno-
genetic distances could be as high as 35% (Gaschen et vations, which will require the scientific community to
al., 2002). Subtypes A, C, and D have spread throughout work together with one common vision and mission. A
Africa, whereas subtype B is dominant in the U.S. and protective vaccine is our best hope of averting a plague
Europe. The distribution of clade-C viruses is now most of catastrophic proportions.
widespread, accounting for about half of the new HIV-1
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